GC Labs successfully concludes day2 of Medlab Middle East 2024

February 07, 2024 02:00 AM AEDT | By Cision

GC Labs successfully concludes day2 of Medlab Middle East 2024 — Image source: Kalkine Media

Recent News

Chemours Corpus Christi Site Wins 2025 Better Project Award for Innova...

Canadian Solar Schedules First Quarter 2025 Earnings Conference Call f...

S&P/ASX 300 Index Rebalancing: Key Changes and Market Impact

From Exchange to Ecosystem Builder: MEXC Celebrates 7th Anniversary at...

YONGIN, South Korea, Feb. 6, 2024 /PRNewswire/ -- GC Labs, a leading clinical laboratory in South Korea, announced that the company concluded day2 with a successful performance at the Medlab Middle East 2024.

An image of GC Labs' booth installed at Medlab Middle East 2024 held at Dubai World Trade Center (DWTC), UAE

Medlab Middle East, the MENA region's largest medical laboratory exhibition, was held at Dubai World Trade Center (DWTC) UAE, from the February 5^th to 8^th. GC Labs participated in this leading exhibition for three consecutive years to strengthen cooperation with major partners in the region and explore new business opportunities.

This year, GC Labs co-hosted a promotion booth with GC MS and Genes Laboratories which are affiliates of GC Holdings to showcase total diagnostic solutions ranging from diagnostic test services to testing reagents and medical devices. The three company's integrated booth, located in Z4.E41 right by the entrance, was crowded with visitors for the first two days.

GC Labs, specifically, caught visitors' attention by promoting diagnostic test items optimized for the demand and environment of the Middle East market. Moreover, they presented a series of pathology tests that was newly opened targeting for global partners.

Furthermore, the signing ceremony between GC Labs and bioLAB, a renowned private clinical laboratory in Bahrain, took place during the exhibition. GC Labs signed a memorandum of understanding (MOU) with bioLAB to transfer its technology and knowledge in the field of cytogenetics. Since two parties have continued cooperation in the send-out business of referring tests, the agreement aims to strengthen their strategic partnerships by making technological advancements and boosting business.

GC Labs officials said, "GC Labs has built credibility and brand awareness as we have successfully implemented business cooperation with various partners in the Middle East. Now is the time to solidify our position and Medlab will be a great stepping stone for us to take a large leap forward in the market," and added, "With the signing of the MOU on tech transfer with bioLAB, we are expected to expand our service offerings beyond existing diagnostic test service and create more lucrative business developments in the Middle East."

GC Labs will continue to exhibit at Medlab Middle East 2024 until February 8 at booth Z4.E41.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.